Ford Motor Co. (NYSE:F) showcased its version of an autonomous vehicle at an event at Phoenix co-working space CO+HOOTS on 2 March, 2016. The company is testing a self-driving Fusion sedan at a facility in Wittmann, where the automaker also performs stress testing on its products.
Ford Motor Company (NYSE:F) belongs to Consumer Goods sector. Its net profit margin is 4.90% and weekly performance is 8.98%. On last trading day company shares ended up at $13.59. Ford Motor Company (NYSE:F) distance from 50-day simple moving average (SMA50) is 10.20%.
On 2 March, Otonomy, Inc. (NASDAQ:OTIC), announced the commercial launch of OTIPRIO (ciprofloxacin otic suspension) in the United States. OTIPRIO was approved by the U.S. Food and Drug Administration (FDA) in December 2015 for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP). OTIPRIO is a single-dose, physician-administered antibacterial and the first product approved by the FDA for this indication.
Otonomy, Inc. (NASDAQ:OTIC) shares advanced 7.31% in last trading session and ended the day at $16.01. OTIC return on assets is -24.60%. Otonomy, Inc. (NASDAQ:OTIC) quarterly performance is -41.97%.
Cesca Therapeutics Inc. (NASDAQ:KOOL), has amended its Certificate of Incorporation to reflect a 1-for-20 reverse stock split effective 5:00pm PST on March 4, 2016. Computershare, the Company’s transfer agent, is acting as the exchange agent for the reverse split. Stockholders of record as of close of business on March 4, 2016 will receive the forms and notices to exchange their existing shares for the new shares from the exchange agent, or from their bank, broker or other nominee holder. Stockholders will not receive fractional shares in connection with the reverse stock split.
On 04 March, Cesca Therapeutics Inc. (NASDAQ:KOOL) shares moved down -6.48% and was closed at $0.20. Cesca Therapeutics Inc. (NASDAQ:KOOL) year to date (YTD) performance is 10.98%.
On 24 February, ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced that its collaboration partner Dexcel Pharma Technologies Ltd. (“Dexcel”) has received approval from the U.S. Food and Drug Administration (“FDA”) of the Abbreviated New Drug Application (“ANDA”) for Donepezil HCl 23mg Tablets. Sales of the product for calendar year 2015 were $44 million, according to IMS Health, with five current generic competitors. ANI and Dexcel expect to begin shipping to customers shortly.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ended the last trading day at $35.20. Company weekly volatility is calculated as 5.06% and price to cash ratio as 2.61. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) showed a weekly performance of 3.71%.
Independent Bank Group, Inc. (NASDAQ:IBTX) shares advanced 3.68% in last trading session and ended the day at $29.88. IBTX return on assets is 0.90%. Independent Bank Group, Inc. (NASDAQ:IBTX) quarterly performance is -23.56%.